Boston Scientific's Q1 cardiovascular segment grew 13.5%, but management cut full-year 2026 organic growth guidance from 10%-11% to 6.5%-8% after unexpected headwinds in electrophysiology and WATCHMAN volumes. Shares plunged about 12% to a 52-week low, driving valuation to roughly 15.0x forward earnings near $50.
In Q1 2026, Boston Scientific's cardiovascular segment delivered 13.5% reported growth, but management slashed full-year organic growth guidance to 6.5%-8.0% from 10%-11% due to unanticipated headwinds in electrophysiology and WATCHMAN implant volumes.
Executives confirmed a flattening in standalone WATCHMAN procedures, expecting flat sequential dollar growth through Q3, while competition from Medtronic’s Varipulse and J&J’s CARTO-integrated solutions intensified, triggering a 12% share price drop to a 52-week low.
Shares are down roughly 46% year-to-date and trade near $50, compressing the forward multiple to about 15.0x expected earnings of $3.38, raising concerns over potential downside risks despite the seemingly attractive valuation.
